Bounded PubMed search run October 27, 2026 — not a systematic review.
Human-administered formulations found in that bounded search, plus animal and laboratory evidence that cannot answer the same questions.
Short answer
Monolaurin is also called glycerol monolaurate or GML. In the bounded PubMed search documented below, human participants received vaginal gels, GML-finished tampons, a nonaqueous nasal gel, or a combination mouthwash. Researchers have also tested vaginal creams in macaques and a gel-like microemulsion in the laboratory. These forms and outcomes are not interchangeable. The human intervention studies mapped here concern local use; they do not show that swallowed capsules, pellets, or powders prevent or treat infection.
| Formulation | Population or system | What was found | Main limitation |
|---|---|---|---|
| 5% vaginal gel | 109 women with bacterial vaginosis | Clinical cure was 17% with monolaurin and 25% with vehicle; no significant difference. | One condition and three-day regimen; not oral use. |
| GML-finished tampon | 225 women; S. aureus was present in the tampons of 41 women | Measured toxin amounts were lower with the GML finish. | Local biomarker result, not treatment of established infection. |
| 0%, 0.5%, or 5% vaginal gel | 36 women over two days (14 control, 13 at 0.5%, 9 at 5%) | The pooled GML groups showed a greater reduction in Candida counts than control; both GML and control gels reduced Gardnerella counts. The gels did not reduce Lactobacillus counts or significantly alter vaginal pH. | Small groups, short follow-up, and microbial-count outcomes. This small, short study did not establish clinical cure. |
| 5% GML nonaqueous nasal gel | 40 healthy volunteers; 14 initially carried S. aureus | After three days, before/after counts fell about 3 log units for S. aureus and coagulase-negative staphylococci. | Uncontrolled microflora study in healthy people; it did not test prevention or treatment of infection. |
| 0.4% epsilon-polylysine + 0.2% glycerol monolaurate mouthwash | 35-person oral-only subgroup in a multi-group human trial | The paper reported 77.14% effectiveness based on oral H. pylori tests becoming negative. | Combination product and study-specific saliva tests; no effect can be assigned to monolaurin alone. |
| 5%, 15%, or 35% vaginal cream | Rhesus macaques | Local exposure and safety were measured. | Animal work, not human treatment efficacy. |
| Gel-like microemulsion | Laboratory Candida system | Released monolaurin and reduced Candida survival in laboratory tests. | No people were treated. |
What has been tested in people?
The clearest negative clinical result comes from a trial of 109 women with bacterial vaginosis. A 5% monolaurin vaginal gel used twice daily for three days was no better than the vehicle gel for clinical cure: 17% versus 25%. Reported adverse events were mostly mild or moderate and did not differ significantly between groups. This result applies to one vaginal product and one condition. PMID 32379102
A 225-woman study compared tampons with and without a GML fiber finish. Staphylococcus aureus was present in the tampons of 41 women; measured toxin amounts were lower with the GML finish. That is a local biomarker result during tampon use, not proof that GML prevents toxic shock or treats an established infection. PMID 19863450
A two-day randomized study assigned 36 women to vaginal gels containing 0% GML (14 women), 0.5% (13), or 5% (9). The pooled GML groups showed a greater reduction in Candida counts than control; both GML and control gels reduced Gardnerella vaginalis counts. The gels did not reduce Lactobacillus counts or significantly alter vaginal pH. No adverse events were reported. This small, short study did not establish clinical cure. PMID 20008774
The nasal study gave 5% GML in a glycol-based nonaqueous gel to 40 healthy volunteers for three days. Fourteen carried S. aureus before treatment. In before/after cultures, the investigators reported an approximately 3-log-unit drop in S. aureus and coagulase-negative staphylococcal counts. This was an uncontrolled microflora study in healthy people: it did not enroll patients with infection or measure whether the gel prevented or treated infection. PMID 32727862
The mouthwash evidence comes from a trial that enrolled 159 symptomatic and 118 asymptomatic participants across several treatment subgroups. The full paper describes the rinse as containing 0.4% epsilon-polylysine (e-polylysine) and 0.2% glycerol monolaurate, while the abstract shortens epsilon-polylysine to ‘lysine’; participants used 20 mL twice daily for one month. In a 35-person oral-only subgroup receiving mouthwash alone, the paper reported 77.14% effectiveness based on oral H. pylori tests becoming negative. Because two active ingredients were combined, the result cannot be attributed to monolaurin alone. The result also depends on the paper's study-specific saliva tests and interpretation of oral H. pylori, and it says nothing about swallowing monolaurin. PMID 25179088; NCT01863823
What remains animal or laboratory evidence?
Researchers tested vaginal creams containing 5%, 15%, or 35% GML in rhesus macaques. The work measured local exposure and safety, not human treatment benefit. PMID 28389267
A gel-like microemulsion released monolaurin and reduced Candida survival in laboratory tests. No people were treated. PMID 35292880
What did the bounded search add or exclude?
The bounded PubMed searches run on October 27, 2026 found five eligible human intervention studies, including the nasal gel study. No other eligible human-administered therapeutic formulation was found. The search also found a 2025 observational cohort linking higher measured serum monolaurin with lower COVID-19 risk, but no monolaurin product was assigned or administered, so it cannot show that any formulation prevents infection. Recent atopic-dermatitis and petrolatum papers tested patient isolates, cells, or animals rather than treating people with a monolaurin formulation. The methods section below gives the exact queries, counts, screening rules, dispositions, and bounded-search limitations. PMID 40141096; PMID 40604030; PMID 42300754
What about swallowed supplements?
A narrative review found no peer-reviewed human clinical evidence for monolaurin used as a swallowed dietary supplement beyond its role as a nutrient; its English-language search ended in April 2018. The new PubMed search likewise found no human trial in which a swallowed monolaurin product was administered to prevent or treat disease. That bounded result does not prove that no study exists in every database, language, registry, or unpublished record. PMID 32952476
Bottom line
The studied forms differ in route, concentration, companion ingredients, population, comparator, and outcome. Before/after microbial counts, a combination mouthwash, a vaginal gel, a tampon finish, an animal cream, or a laboratory carrier cannot establish an effective dose or clinical benefit for a swallowed retail supplement. This article maps a documented PubMed search; it is not a medical recommendation or a systematic review.
Search methods and limitations
Search date: October 27, 2026.
- Query A — 77 records:
("monolaurin"[Title/Abstract] OR "glycerol monolaurate"[Title/Abstract] OR "glyceryl monolaurate"[Title/Abstract] OR "glyceryl laurate"[Title/Abstract] OR "lauric acid monoglyceride"[Title/Abstract] OR "monoglycerol laurate"[Title/Abstract] OR "monolauroylglycerol"[Title/Abstract]) AND humans[MeSH Terms] - Query B — 29 records:
("monolaurin"[Title/Abstract] OR "glycerol monolaurate"[Title/Abstract] OR "glyceryl monolaurate"[Title/Abstract] OR "glyceryl laurate"[Title/Abstract] OR "lauric acid monoglyceride"[Title/Abstract] OR "monoglycerol laurate"[Title/Abstract] OR "monolauroylglycerol"[Title/Abstract]) AND (gel[Title/Abstract] OR cream[Title/Abstract] OR ointment[Title/Abstract] OR intranasal[Title/Abstract] OR nasal[Title/Abstract] OR vaginal[Title/Abstract] OR oral[Title/Abstract] OR mouthwash[Title/Abstract] OR rinse[Title/Abstract] OR tampon[Title/Abstract] OR capsule[Title/Abstract] OR tablet[Title/Abstract] OR pellet[Title/Abstract] OR powder[Title/Abstract] OR supplement[Title/Abstract] OR formulation[Title/Abstract]) AND humans[MeSH Terms] - Query C — 52 records:
"monolaurin"[Supplementary Concept] AND humans[MeSH Terms]
Screening rule: Query A's 77 titles and Query C's 52 titles were screened for possible human administration. Query B's 29 titles and abstracts were screened in full, with candidate abstracts or full text checked as needed. A peer-reviewed record was included only when people were administered a monolaurin- or GML-containing formulation and a human outcome after exposure was reported. Combination products were included but labeled. Animal, in-vitro, ex-vivo, cell, formulation-development, review, analog, food or coconut-oil, and observational biomarker records were excluded when no monolaurin formulation was administered.
Eligible records: Five records were eligible: PMID 32727862 (nasal gel), PMID 32379102 (vaginal gel), PMID 25179088 (epsilon-polylysine plus GML mouthwash), PMID 20008774 (vaginal microflora gel), and PMID 19863450 (GML-finished tampons). No eligible swallowed-monolaurin intervention was found.
Query B dispositions (all 29):
- Eligible: 32727862, 32379102, 25179088, 20008774, 19863450
- Human-linked, but no administered monolaurin formulation: 40604030, 40141096, 26811613, 26005054, 21603626, 20921308
- Relevant preclinical or laboratory only: 42300754, 40771311, 35292880, 32371599, 28389267, 26057743, 24748386, 19838303, 18838587, 16475828, 15793101
- Other compound, carrier, or search false positive: 42616176, 41036846, 40795557, 40781368, 39024566, 31221331, 24814881
Bounded-search limitations: This was a bounded PubMed search, not a systematic review. It did not exhaust Embase, Scopus, Web of Science, Google Scholar, registries, regulatory databases, commercial catalogs, non-English literature, or unpublished evidence. PubMed counts are returned record counts, not counts of eligible trials.
References
- PMID 32379102 — 5% vaginal gel randomized trial
- PMID 19863450 — GML-finished tampon study
- PMID 20008774 — short vaginal-gel study
- PMID 32727862 — 5% GML nonaqueous nasal-gel microflora study
- PMID 25179088 — epsilon-polylysine plus GML mouthwash trial
- NCT01863823 — mouthwash trial registration
- PMID 28389267 — rhesus vaginal-cream study
- PMID 35292880 — laboratory gel-like microemulsion
- PMID 32952476 — dietary-supplement narrative review
- PMID 40141096 — observational serum-monolaurin cohort
- PMID 40604030 — patient-isolate atopic-dermatitis study
- PMID 42300754 — laboratory and rabbit petrolatum study